Literature DB >> 28721303

Value of 99mTc-MDP SPECT/CT and 18F-FDG PET/CT scanning in the evaluation of malignantly transformed fibrous dysplasia.

Wei-Jun Wei1,2, Zhen-Kui Sun1, Chen-Tian Shen1, Xin-Yun Zhang1, Juan Tang3, Hong-Jun Song1, Zhong-Ling Qiu1, Quan-Yong Luo1.   

Abstract

Although fibrous dysplasia is not considered a potentially premalignant disorder, malignant transformation occurs. Because of its rarity, radiographic features of malignantly transformed fibrous dysplasia on cross-sectional imaging modalities are less recognized, making diagnosis and differential diagnosis of the disease quite difficult in clinical practice. In this study, we analyzed the clinical characteristics, imaging features, pathology findings and surgery strategies of 19 malignantly transformed fibrous dysplasia. We found that there was significant male predominance in this specific cohort (13/6). While osteosarcoma (63.2%) was the most frequently occurring neoplasm secondary to fibrous dysplasia, other less commonly malignantly changed types included fasciculated sarcoma, malignant fibrous histiocytoma, fibrosarcoma and chondrosarcoma. We found that the diagnostic value of single modality imaging method, like conventional X-ray, computed tomography or non-contrast magnetic resonance imaging, was limited mainly because of a lack of whole-body metabolic information. In contrast, we highlighted that 99mTc-MDP SPECT/CT and/or 18F-FDG PET/CT scanning could exert a pivotal role in the management of malignantly transformed fibrous dysplasia by guiding precise biopsy and optimizing surgery options.

Entities:  

Keywords:  Fibrous dysplasia; fibrosarcoma; malignant transformation; nuclear medicine imaging; osteosarcoma

Year:  2017        PMID: 28721303      PMCID: PMC5511119     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  44 in total

1.  The natural history of fibrous dysplasia. An orthopaedic, pathological, and roentgenographic study.

Authors:  W H HARRIS; H R DUDLEY; R J BARRY
Journal:  J Bone Joint Surg Am       Date:  1962-03       Impact factor: 5.284

2.  Bisphosphonate therapy in fibrous dysplasia.

Authors:  J M Lane; S N Khan; W J O'Connor; M Nydick; J P Hommen; R Schneider; E Tomin; J Brand; J Curtin
Journal:  Clin Orthop Relat Res       Date:  2001-01       Impact factor: 4.176

3.  Adamantinoma.

Authors:  Darlene M Holden; Michael J Joyce; Murali Sundaram
Journal:  Orthopedics       Date:  2014-06       Impact factor: 1.390

Review 4.  Fibrous dysplasia. Pathophysiology, evaluation, and treatment.

Authors:  Matthew R DiCaprio; William F Enneking
Journal:  J Bone Joint Surg Am       Date:  2005-08       Impact factor: 5.284

5.  Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia.

Authors:  Malissa Dawn Thomsen; Lars Rejnmark
Journal:  Calcif Tissue Int       Date:  2014-01-04       Impact factor: 4.333

6.  Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.

Authors:  Y Sugawara; S J Fisher; K R Zasadny; P V Kison; L H Baker; R L Wahl
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

7.  Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.

Authors:  Muriel S Parisi; Beatriz Oliveri; Carlos A Mautalen
Journal:  Bone       Date:  2003-10       Impact factor: 4.398

8.  Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.

Authors:  G C Isaia; R Lala; C Defilippi; P Matarazzo; M Andreo; C Roggia; G Priolo; C de Sanctis
Journal:  Calcif Tissue Int       Date:  2002-07-23       Impact factor: 4.333

9.  Normal vision despite narrowing of the optic canal in fibrous dysplasia.

Authors:  Janice S Lee; Edmond FitzGibbon; John A Butman; Craig R Dufresne; Harvey Kushner; Shlomo Wientroub; Pamela G Robey; Michael T Collins
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  The role of radionuclide bone scintigraphy in fibrous dysplasia of bone.

Authors:  Yuan Zhibin; Luo Quanyong; Chen Libo; Zhu Jun; Lu Hankui; Zhu Jifang; Zhu Ruisen
Journal:  Clin Nucl Med       Date:  2004-03       Impact factor: 7.794

View more
  1 in total

1.  Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.

Authors:  Wouter van der Bruggen; Dennis Vriens; Maartje E Meier; Frits Smit; Elizabeth M Winter; Lioe-Fee de Geus-Oei; Natasha M Appelman-Dijkstra
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.